177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Exclusion criteria

• ✕. Has primary bone marrow disorder (e.g. leukemia, myeloproliferative or myelodysplastic disorder)
• ✕. Presence of iron deficiency or other hematological disorders that may cause anemia and cytopenia
• ✕. Has participated in a study of an investigational agent or an investigational device within 4 weeks of the first dose of study therapy
• ✕. Has received treatment with an approved systemic therapy within 2 weeks of dosing or has not yet recovered (i.e., grade ≤1 or baseline) from any acute toxicities attributed to the systemic therapy.
• ✕. Has received radiation therapy or major surgery within 14 days of first administration of study drug.
• ✕. Has received radiopharmaceutical agents in the past (e.g., Strontium-89, PSMA-targeted radioligand therapy)
• ✕. Has received prior PSMA-targeting therapy
• ✕. Another malignancy that is progressing or requires active treatment with the exception of non-melanoma skin cancer that has undergone potentially curative therapy